Disc Medicine, Inc. (IRON): who owns it and who trades it
As of Nov 16, 2026, IRON insiders reported 97 open-market sales worth $48.8M and no purchases in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Bitterman (Director), with $26.7M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Disc Medicine
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IRON
216 funds and institutions reported IRON shares worth $3.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 12.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 4.89M | 12.81% | $358M | -12% |
| BlackRock, Inc. | 2.47M | 6.46% | $181M | +9% |
| Ra Capital Management, L.P. | 2.45M | 6.41% | $179M | No change |
| JPMorgan Chase & Co | 1.88M | 4.91% | $140M | – |
| T. Rowe Price Associates | 1.88M | 4.91% | $137M | +21% |
| Wellington Management Group LLP | 1.74M | 4.56% | $127M | +0% |
| State Street Corp | 1.65M | 4.32% | $121M | -3% |
| Vestal Point Capital, LP | 1.55M | 4.06% | $113M | +121% |
| Atlas Venture Life Science Advisors, LLC | 1.51M | 3.96% | $111M | No change |
| Vanguard Capital Management LLC | 1.37M | 3.58% | $100M | -0% |
| Frazier Life Sciences Management, L.P. | 1.35M | 3.55% | $99.1M | No change |
| TCG Crossover Management, LLC | 1.34M | 3.51% | $98.1M | No change |
| Bvf Inc | 1.15M | 3.02% | $84.4M | -9% |
| Woodline Partners LP | 958,281 | 2.51% | $70.1M | No change |
| Siren, L.L.C. | 888,401 | 2.33% | $65M | -10% |
| Logos Global Management LP | 875,000 | 2.29% | $64M | +56% |
| Opaleye Management Inc. | 855,000 | 2.24% | $62.5M | +103% |
| Geode Capital Management, LLC | 789,724 | 2.07% | $57.8M | +6% |
| Assenagon Asset Management S.A. | 768,316 | 2.01% | $56.2M | +41% |
| Deerfield Management Company, L.P. | 657,000 | 1.72% | $48.1M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IRON insiders reported $0 of open-market purchases and $48.8M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | William Jacob Savage | Chief Medical Officer | Sale plan | 16,035 | $85.09 | $1.4M | Form 4 |
| Oct 21, 2026 | Kevin Bitterman | Director | Sale plan | 13,783 | $80.23 | $1.1M | Form 4 |
| Oct 21, 2026 | Kevin Bitterman | Director | Sale plan | 11,470 | $80.23 | $920K | Form 4 |
| Oct 21, 2026 | Kevin Bitterman | Director | Sale plan | 266 | $80.23 | $21.3K | Form 4 |
| Oct 20, 2026 | Kevin Bitterman | Director | Sale plan | 2,869 | $79.95 | $229K | Form 4 |
| Oct 20, 2026 | Kevin Bitterman | Director | Sale plan | 2,388 | $79.95 | $191K | Form 4 |
| Oct 20, 2026 | Kevin Bitterman | Director | Sale plan | 55 | $79.95 | $4.4K | Form 4 |
| Oct 19, 2026 | Kevin Bitterman | Director | Sale plan | 5,937 | $79.97 | $475K | Form 4 |
| Oct 19, 2026 | Kevin Bitterman | Director | Sale plan | 4,942 | $79.97 | $395K | Form 4 |
| Oct 19, 2026 | Kevin Bitterman | Director | Sale plan | 115 | $79.97 | $9.2K | Form 4 |
| Sep 11, 2026 | Kevin Bitterman | Director | Sale | 27,136 | $70.11 | $1.9M | Form 4 |
| Sep 4, 2026 | Kevin Bitterman | Director | Sale plan | 912 | $79.96 | $72.9K | Form 4 |
| Sep 4, 2026 | Kevin Bitterman | Director | Sale plan | 18 | $79.96 | $1.4K | Form 4 |
| Sep 4, 2026 | Kevin Bitterman | Director | Sale plan | 759 | $79.96 | $60.7K | Form 4 |
| Sep 3, 2026 | Kevin Bitterman | Director | Sale plan | 54 | $79.98 | $4.3K | Form 4 |
| Sep 3, 2026 | Kevin Bitterman | Director | Sale plan | 2,810 | $79.98 | $225K | Form 4 |
| Sep 3, 2026 | Kevin Bitterman | Director | Sale plan | 2,339 | $79.98 | $187K | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 26,542 | $80.17 | $2.1M | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 22,090 | $80.17 | $1.8M | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 10 | $80.98 | $810 | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 9 | $80.98 | $729 | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 2 | $80.98 | $162 | Form 4 |
| Sep 2, 2026 | Kevin Bitterman | Director | Sale plan | 511 | $80.17 | $41K | Form 4 |
| Sep 1, 2026 | Kevin Bitterman | Director | Sale plan | 70 | $79.95 | $5.6K | Form 4 |
| Sep 1, 2026 | Kevin Bitterman | Director | Sale plan | 58 | $79.95 | $4.6K | Form 4 |
| Sep 1, 2026 | Kevin Bitterman | Director | Sale plan | 1 | $79.95 | $80 | Form 4 |
| Aug 25, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 8,796 | $83.12 | $731K | Form 4 |
| Aug 24, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 300 | $82.53 | $24.8K | Form 4 |
| Aug 17, 2026 | John D Quisel | CEO | Sale | 12,712 | $79.20 | $1M | Form 4 |
| Aug 17, 2026 | John D Quisel | CEO | Sale | 11,888 | $79.84 | $949K | Form 4 |
| Aug 17, 2026 | John D Quisel | CEO | Sale | 8,400 | $78.11 | $656K | Form 4 |
| Aug 12, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 804 | $82.64 | $66.4K | Form 4 |
| Aug 6, 2026 | Rahul Khara | Chief Legal Officer | Sale | 5,000 | $80.00 | $400K | Form 4 |
| Jul 13, 2026 | John D Quisel | CEO | Sale | 16,896 | $74.95 | $1.3M | Form 4 |
| Jul 13, 2026 | John D Quisel | CEO | Sale | 6,400 | $76.05 | $487K | Form 4 |
| Jul 13, 2026 | John D Quisel | CEO | Sale | 9,704 | $74.27 | $721K | Form 4 |
| Jul 7, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 100 | $82.50 | $8.2K | Form 4 |
| Jun 29, 2026 | Rahul Khara | Chief Legal Officer | Sale | 1,649 | $75.00 | $124K | Form 4 |
| Jun 26, 2026 | Rahul Khara | Chief Legal Officer | Sale | 851 | $75.00 | $63.8K | Form 4 |
| Jun 26, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 300 | $72.50 | $21.8K | Form 4 |
| Jun 22, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 9,700 | $72.66 | $705K | Form 4 |
| Jun 18, 2026 | Rahul Khara | Chief Legal Officer | Sale | 500 | $71.62 | $35.8K | Form 4 |
| Jun 18, 2026 | Rahul Khara | Chief Legal Officer | Sale | 1,600 | $70.73 | $113K | Form 4 |
| Jun 18, 2026 | Rahul Khara | Chief Legal Officer | Sale | 5,400 | $69.94 | $378K | Form 4 |
| Jun 18, 2026 | John D Quisel | CEO | Sale | 1,551 | $71.61 | $111K | Form 4 |
| Jun 18, 2026 | John D Quisel | CEO | Sale | 9,522 | $70.70 | $673K | Form 4 |
| Jun 18, 2026 | John D Quisel | CEO | Sale | 22,927 | $69.92 | $1.6M | Form 4 |
| Jun 16, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 6,961 | $69.92 | $487K | Form 4 |
| Jun 16, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 11,651 | $68.76 | $801K | Form 4 |
| Apr 14, 2026 | Jean M. Franchi | CFO | Sale | 6,257 | $69.24 | $433K | Form 4 |
| Apr 13, 2026 | William Jacob Savage | Chief Medical Officer | Sale | 2,200 | $66.81 | $147K | Form 4 |
| Apr 13, 2026 | William Jacob Savage | Chief Medical Officer | Sale | 3,531 | $66.12 | $233K | Form 4 |
| Apr 13, 2026 | Jean M. Franchi | CFO | Sale | 400 | $69.00 | $27.6K | Form 4 |
| Mar 2, 2026 | William Jacob Savage | Chief Medical Officer | Sale | 4,392 | $65.52 | $288K | Form 4 |
| Mar 2, 2026 | William Jacob Savage | Chief Medical Officer | Sale | 2,986 | $66.41 | $198K | Form 4 |
| Feb 25, 2026 | Jean M. Franchi | CFO | Sale | 353 | $69.06 | $24.4K | Form 4 |
| Feb 18, 2026 | Jean M. Franchi | CFO | Sale | 3,684 | $65.89 | $243K | Form 4 |
| Feb 18, 2026 | Jean M. Franchi | CFO | Sale | 3,397 | $65.01 | $221K | Form 4 |
| Feb 17, 2026 | Jean M. Franchi | CFO | Sale | 4,075 | $62.86 | $256K | Form 4 |
| Feb 17, 2026 | Rahul Khara | Chief Legal Officer | Sale | 2,853 | $62.86 | $179K | Form 4 |
| Feb 17, 2026 | Pamela Stephenson | Chief Commercial Officer | Sale | 5,531 | $62.86 | $348K | Form 4 |
| Feb 17, 2026 | William Jacob Savage | Chief Medical Officer | Sale | 3,256 | $62.86 | $205K | Form 4 |
| Feb 17, 2026 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sale | 3,231 | $62.86 | $203K | Form 4 |
| Feb 17, 2026 | John D Quisel | CEO | Sale | 13,264 | $62.86 | $834K | Form 4 |
| Jan 20, 2026 | Rahul Khara | Chief Legal Officer | Sale | 1,000 | $69.74 | $69.7K | Form 4 |
| Jan 2, 2026 | Rahul Khara | Chief Legal Officer | Sale | 1,157 | $79.27 | $91.7K | Form 4 |
| Jan 2, 2026 | Rahul Khara | Chief Legal Officer | Sale | 4,993 | $78.62 | $393K | Form 4 |
| Jan 2, 2026 | Rahul Khara | Chief Legal Officer | Sale | 350 | $77.67 | $27.2K | Form 4 |
| Dec 17, 2025 | Kevin Bitterman | Director | Sale | 393 | $91.47 | $35.9K | Form 4 |
| Dec 17, 2025 | Kevin Bitterman | Director | Sale | 148 | $91.47 | $13.5K | Form 4 |
| Dec 17, 2025 | Kevin Bitterman | Director | Sale | 213 | $91.47 | $19.5K | Form 4 |
| Dec 16, 2025 | Kevin Bitterman | Director | Sale | 18,666 | $91.24 | $1.7M | Form 4 |
| Dec 16, 2025 | Kevin Bitterman | Director | Sale | 35,898 | $91.24 | $3.3M | Form 4 |
| Dec 16, 2025 | Kevin Bitterman | Director | Sale | 14,359 | $91.24 | $1.3M | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 1,572 | $92.01 | $145K | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 11,427 | $91.18 | $1M | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 2,049 | $92.01 | $189K | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 14,811 | $91.18 | $1.4M | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 3,921 | $92.01 | $361K | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 28,913 | $91.18 | $2.6M | Form 4 |
| Dec 15, 2025 | Kevin Bitterman | Director | Sale | 7,000 | $91.87 | $643K | Form 4 |
| Dec 15, 2025 | William Jacob Savage | Chief Medical Officer | Sale | 300 | $92.23 | $27.7K | Form 4 |
| Dec 15, 2025 | William Jacob Savage | Chief Medical Officer | Sale | 9,151 | $91.44 | $837K | Form 4 |
| Dec 15, 2025 | William Jacob Savage | Chief Medical Officer | Sale | 3,642 | $90.60 | $330K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 2,005 | $92.58 | $186K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 16,403 | $92.05 | $1.5M | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 3,852 | $92.58 | $357K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 3,446 | $93.80 | $323K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 8,527 | $92.05 | $785K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 1,793 | $93.80 | $168K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 6,570 | $92.05 | $605K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 1,540 | $92.58 | $143K | Form 4 |
| Dec 12, 2025 | Kevin Bitterman | Director | Sale | 1,371 | $93.80 | $129K | Form 4 |
| Dec 11, 2025 | John D Quisel | CEO | Sale | 2,419 | $90.97 | $220K | Form 4 |
| Dec 11, 2025 | John D Quisel | CEO | Sale | 4,337 | $92.21 | $400K | Form 4 |
| Dec 11, 2025 | John D Quisel | CEO | Sale | 16,356 | $92.96 | $1.5M | Form 4 |
| Dec 11, 2025 | John D Quisel | CEO | Sale | 16,888 | $93.65 | $1.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin Bitterman | Director | – | $26.7M | Oct 21, 2026 |
| John D Quisel | Chief Executive Officer, Director | – | $12M | Aug 17, 2026 |
| William Jacob Savage | Chief Medical Officer | – | $3.6M | Nov 10, 2026 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | – | $3M | Aug 25, 2026 |
| Rahul Khara | Chief Legal Officer | – | $1.9M | Aug 6, 2026 |
| Jean M. Franchi | Chief Financial Officer | – | $1.2M | Apr 14, 2026 |
| Pamela Stephenson | Chief Commercial Officer | – | $348K | Feb 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IRON short interest
High short interest. 15.1% of IRON shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.86M IRON shares were sold short, 15.1% of the shares outstanding, down 8.0% from the report before. At the average daily volume of 2.16M shares, buying them all back would take about 3.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.86M | 15.07% | -8% | 2.16M | 3.2 |
| Oct 15, 2026 | 7.46M | 19.42% | +3% | 701,301 | 10.6 |
| Sep 30, 2026 | 7.27M | 18.94% | +1% | 568,317 | 12.8 |
| Sep 15, 2026 | 7.21M | 18.77% | -2% | 528,932 | 13.6 |
| Aug 31, 2026 | 7.37M | 19.18% | +0% | 442,810 | 16.6 |
| Aug 14, 2026 | 7.34M | 19.12% | -1% | 295,889 | 24.8 |
| Jul 31, 2026 | 7.39M | 19.26% | +1% | 353,401 | 20.9 |
| Jul 15, 2026 | 7.29M | 19.09% | +15% | 675,783 | 10.8 |
| Jun 30, 2026 | 6.36M | 16.66% | +6% | 995,180 | 6.4 |
| Jun 15, 2026 | 6.01M | 15.73% | +0% | 427,108 | 14.1 |
| May 29, 2026 | 6.00M | 15.70% | +6% | 411,197 | 14.6 |
| May 15, 2026 | 5.67M | 14.84% | +2% | 537,289 | 10.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Disc Medicine company events
Disc Medicine filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (job cuts). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 22, 2026AgreementDisc Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto, related to an underwritten public offering by the Company of… Filing
- Oct 19, 2026AnnouncementThe Company will host a webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria. Filing
- Sep 10, 2026AnnouncementThe Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following a… Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AgreementDisc Medicine, Inc. entered into a First Amendment to Loan Agreement to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and collateral agent for the… Filing
- Jun 24, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 27, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 17, 2026AnnouncementShared information with investors. Filing
- Feb 13, 2026AnnouncementThe Company received a CRL from the FDA for the Company’s NDA for bitopertin as a treatment for patients with EPP. Item 9.01 Financial Statements and Exhibits. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 8, 2025AnnouncementDisc Medicine, Inc. held a previously-announced conference call and webcast to review the Company's data presented at the 67th American Society of Hematology Annual Meeting and Exposition and the Company's operational plans. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Disc Medicine financials
Famous investors that hold IRON
3 of the 50 well-known investors we track reported holding IRON in their latest 13F filing. The largest position is Ken Griffin's, worth $8.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 131,347 | $8.6M | 0.0% | -37% |
| Israel Englander · Millennium Management | Q3 2026 | 53,214 | $3.5M | 0.0% | -50% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 27,846 | $1.8M | 0.0% | -3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IRON in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 26, 2026 | AI DMI LLC | 13D/A | 6.6% |
| Oct 26, 2026 | AI DMI LLC | 13D/A | 6.6% |
Questions about Disc Medicine, Inc. (IRON) stock
Who owns the most IRON stock?
The largest reported owner of Disc Medicine, Inc. (IRON) is FMR LLC (Fidelity), with 12.8% of the company. In total, 216 funds and institutions reported holding IRON at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IRON insiders buying or selling?
In the last 12 months, IRON insiders reported no open-market purchases and 97 sales worth $48.8M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in IRON?
As of Oct 30, 2026, 6.86M IRON shares were sold short, 15.1% of the shares outstanding, down 8.0% from the report before. At the average daily volume of 2.16M shares, buying them all back would take about 3.2 trading days (days to cover). See the history.
Which famous investors hold IRON?
3 of the 50 well-known investors we track reported IRON in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $8.6M. See all holders.
Executive pay
Disc Medicine's chief executive was paid a total of $10M for the year ended Dec 31, 2025, up 10% from $9.1M the year before. In the last 12 months, Disc Medicine's executives and directors bought no stock on the open market and sold $48.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.